Immix Biopharma (IMMX) Other Non-Current Liabilities (2020 - 2021)
Immix Biopharma (IMMX) posted Other Non-Current Liabilities of $23.4 million for Q4 2021, up 3972.14% sequentially from $575000.0 in Q4 2020, and up 3972.14% YoY from $575000.0 in Q4 2020.
Powered by 
Analysis
Immix Biopharma (IMMX) Other Non-Current Liabilities (2020 - 2021) Analysis & Trends
Immix Biopharma has reported Other Non-Current Liabilities for 2 years, with the latest figure at $23.4 million in Q4 2021.
- Quarterly Other Non-Current Liabilities rose 3972.14% year-over-year to $23.4 million in Q4 2021, while the trailing twelve-month figure through Dec 2021 was $23.4 million (up 3972.14% YoY) and the FY2021 annual result came in at $23.4 million, up 3972.14% from the prior year.
- Other Non-Current Liabilities grew to $23.4 million in Q4 2021 per IMMX's latest filing, from $575000.0 in the prior quarter.
- Over five years, Other Non-Current Liabilities peaked at $23.4 million in Q4 2021 and troughed at $575000.0 in Q4 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Immix Biopharma | 889.29 Mn | 889.29 Mn | - |